Molecularly Aged Protein States as Targets for Drug Design and Delivery in Neurodegenerative Diseases
Pharmaceutics · 18.11.2026 · 18 (11) · 1485
DOI: 10.3390/pharmaceutics18111485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 18.11.2026. Verfasst von Reem Alromaihi und 7 weiteren Autor:innen. Die Arbeit nennt 258 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qassim University.
Abstract (Originalsprache)
Neurodegenerative drug discovery usually represents a protein target by its gene, canonical sequence, and one or a few structures. That representation can miss the molecular history accumulated by proteins that persist in the brain. Spontaneous chemistry, incomplete repair, altered turnover, proteolysis, phase transitions, and assembly remodeling generate states that may differ from the canonical target in exposure, function, and therapeutic accessibility. We call compositionally resolved species age-generated proteoforms and use molecularly aged protein states when the exact composition remains uncertain. This Review develops a target-state framework for Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis and frontotemporal dementia, Huntington disease, and multiple sclerosis. It separates detection from age association, causality, brain exposure, proximal target engagement, and clinical evidence. Disease-specific analyses connect tau and amyloid-beta proteoforms, alpha-synuclein and lysosomal or mitochondrial assemblies, TDP-43 loss-of-function states, and persistent myelin or extracellular-matrix states to rational modalities and critical validation experiments. Repair, selective removal, stabilization, state-selective antibodies and small molecules, intrabodies, replacement, and synthesis control are evaluated together with blood–brain barrier transport, cellular and organelle access, pharmacokinetics, and pharmacodynamics. Each class of target state is mapped to the delivery constraint it imposes and the platform for which a precedent exists, and the exposure requirements that state selectivity implies are set out explicitly, including the fraction of a pool that must be engaged, the duration required to move a slowly accumulating state, and the consequences for dosing interval and pharmacodynamic biomarker choice. The aggregate-directed amyloid antibodies are analysed as the existing clinical test of the framework and of its limits. Machine learning remains central to proteoform identification, multimodal prioritization, structure modeling, and molecular design, provided that labels and prospective tests preserve target-state identity. Classical quantum chemistry can address bounded reaction and recognition problems. Quantum computing is treated as an exploratory implementation that requires matched classical baselines and explicit resources. The central requirement is not that an old protein be abnormal, but that a defined disease-relevant state can be selectively engaged while preserving the functional pool.
Förderung
- Qassim University
Zitieren
APA
Alromaihi, R., Almerdasi, S. A., Almusallam, A. A., Alromaihi, M., Aljohani, W. A., Khan, M. A., Khan, A., & Allemailem, K. S. (2026). Molecularly Aged Protein States as Targets for Drug Design and Delivery in Neurodegenerative Diseases. Pharmaceutics, 18(11), 1485. https://doi.org/10.3390/pharmaceutics18111485
Vancouver
Alromaihi R, Almerdasi SA, Almusallam AA, Alromaihi M, Aljohani WA, Khan MA, et al. Molecularly Aged Protein States as Targets for Drug Design and Delivery in Neurodegenerative Diseases. Pharmaceutics. 2026;18(11):1485. doi:10.3390/pharmaceutics18111485
BibTeX
@article{Alromaihi2026,
author = {Alromaihi, Reem and Almerdasi, Suleman Abdullah and Almusallam, Abdulrahman Abdullah and Alromaihi, Mona and Aljohani, Waad A. and Khan, Masood Alam and Khan, Arif and Allemailem, Khaled S.},
title = {Molecularly Aged Protein States as Targets for Drug Design and Delivery in Neurodegenerative Diseases},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1485},
doi = {10.3390/pharmaceutics18111485}
}
EUVIMED